NCT05346861: Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Therapeutic Antibody, Chemotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have a history of Herceptin/trastuzumab-containing chemotherapy in neoadjuvant, adjuvant, or recurrence/ metastatic setting; Patients must have a history of pyrotinib-containing chemotherapy in neoadjuvant or recurrence/ metastatic setting
Exclusions: Patients with leptomeningeal metastasis or unstable brain metastasis; Patients with more than 2 systemic treatment in the recurrence/ metastatic setting

Comments are closed.

Up ↑